Thomas Wolf, MD
Family Medicine · Fremont, NENPI 1659305506
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,717 of the $5,725 with a category attached, or 82.4%. It is spread thinly across 47 manufacturers, the largest accounting for just 21.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,876 and has fallen 58.4% since, to $781 in 2025. Among family medicine clinicians in NE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 279 payments — averaging $20.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim International GmbH$1K
- AbbVie$877
- Amgen$418
- Boehringer Ingelheim$369
- Pfizer$317
- AstraZeneca$292
- plus $2K from 41 others
Across 1,506 payments — averaging $5422.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$3.6M
- Pfizer$2.1M
- Merck$1.2M
- GSK$538K
- Boehringer Ingelheim$358K
- AstraZeneca$159K
- plus $307K from 8 others
What the payments were for
- Travel & lodging$88015%
- Food & beverage$4,71782%
- Education$631%
- Gifts$200%
- Other$451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,725 in reported general payments places this provider in the 90th percentile of 981 family medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 246 | $248,734 |
| JardianceEmpagliflozin | 148 | $131,059 |
| XareltoRivaroxaban | 96 | $101,840 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 90 | $83,677 |
| OzempicSemaglutide | 68 | $81,695 |
| JanuviaSitagliptin Phosphate | 51 | $39,938 |
| Tresiba Flextouch U-200Insulin Degludec | 42 | $38,461 |
| XifaxanRifaximin | 11 | $36,510 |
| FarxigaDapagliflozin Propanediol | 30 | $33,183 |
| TrulicityDulaglutide | 16 | $29,841 |
| EntrestoSacubitril/Valsartan | 15 | $28,924 |
| MyrbetriqMirabegron | 42 | $25,430 |
| Tresiba Flextouch U-100Insulin Degludec | 31 | $24,071 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 42 | $23,122 |
| ProliaDenosumab | 11 | $19,087 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $317 | $248,734246 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Glyxambi | $369 | $149,720182 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $14 | $117,199149 claims |
| Johnson & JohnsonXarelto | $210 | $101,84096 claims |
| Novo NordiskOzempic | $184 | $81,69568 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $292 | $56,17953 claims |
| MerckJanuvia | $58 | $39,93851 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $54 | $36,51011 claims |
| Lilly USA, LLCTrulicity | $213 | $29,84116 claims |
| NovartisEntresto | $122 | $28,92415 claims |
| Astellas Pharma US IncMyrbetriq | $62 | $25,43042 claims |
| AmgenProlia | $418 | $19,08711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 981 family medicine providers in Nebraska.
Other family medicine in Fremont
- Andrea VermaasFremont$11K
- Michael IsraelLincoln$375K
- Francisco DozonNorfolk$238K
- Randy KohlLincoln$67K
- James OmelGrand Island$67K
- Gerard StanleyOmaha$50K
- Jared KramerSt Paul$41K
- Randolph WaldmanHebron$27K
- Brian FinleyBellevue$20K
- William FitzgibbonsElkhorn$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.